NCT00462072View on ClinicalTrials.gov

Centocor Microarray Study of Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

August 31, 2010

Conditions
Rheumatoid ArthritisPsoriatic ArthritisPsoriasisCrohn's Disease
Interventions
DRUG

Infliximab

Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.

Trial Locations (1)

14642

University of Rochester, Rochester

Sponsors

Collaborators (1)

Centocor, Inc.
All Listed Sponsors
collaborator

Centocor, Inc.

INDUSTRY

lead

University of Rochester

OTHER